Manejo expectante en preeclampsia severa lejos del término. Revisión de la literatura y protocolo de manejo.

  • César Augusto Rendón Universidad del Cauca Departamento de Ginecología y Obstetricia
  • Roberth Alirio Ortiz Universidad del Cauca Departamento de Ginecología y Obstetricia
Palabras clave: Pre-eclampsia, resultados del embarazo, embarazo, recién nacido

Resumen

La meta principal de la conducta expectante en mujeres con preeclampsia grave lejos del término, es mejorar el resultado neonatal sin poner en riesgo la salud materna. Los estudios sugieren que el manejo expectante en preeclampsia de aparición temprana, puede estar asociado con la disminución de la morbilidad neonatal, sin embargo también concluyen que se necesitan más estudios para evaluar la seguridad materna. El objetivo de esta revisión de tema es evaluar la evidencia actual respecto al manejo de la preeclampsia severa lejos del término.

Descargas

Los datos de descargas todavía no están disponibles.

Disciplinas:

obstetricia

Lenguajes:

es

Agencias de apoyo:

Universidad del Cauca, Departamento de Ginecología y Obstetricia

Referencias bibliográficas

Conde-Agudelo A, Belizán JM, Lammers C. Maternal-perinatal morbidity and mortality associated with adolescent pregnancy in Latin America: Cross-sectional study. Am J Obstet Gynecol. 2005 Feb;192(2):342–9.

Cousens S, Blencowe H, Stanton C, Chou D, Ahmed S, Steinhardt L, et al. National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis. Lancet. 2011 Apr 16; 377(9774):1319–30.

Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006 Apr 1; 367(9516):1066–74.

Papageorghiou AT, Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol. 2007 Apr; 19(2):103–9.

Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007 May 26; 369(9575):1791–8.

Diehl CL, Brost BC, Hogan MC, Elesber AA, Offord KP, Turner ST, et al. Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. Am J Obstet Gynecol. 2008 May; 198(5):e11–13.

Spaan JJ, Sep SJS, van Balen VL, Spaanderman MEA, Peeters LLH. Metabolic syndrome as a risk factor for hypertension after preeclampsia. Obstet Gynecol. 2012 Aug; 120(2 Pt 1):311–7.

Berks D, Steegers EAP, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol. 2009 Dec; 114(6):1307–14.

Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005 Mar 26; 365(9461):785–99.

Xia Y, Zhou CC, Ramin SM, Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol Baltim Md 1950. 2007 Sep 15;179(6):3391–5.

Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol CJASN. 2007 May; 2(3):543–9.

Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int. 2009 Oct; 76(8):831–7.

Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007 May 26; 369(9575):1791–8.

Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011 Aug; 66(8):497–506.

Lam C, Lim K-H, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005 Nov; 46(5):1077–85.

Haddad B, Sibai BM. Expectant management in pregnancies with severe pre-eclampsia. Semin Perinatol. 2009 Jun; 33(3):143–51.

ACOG Committee on Practice Bulletins-- Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002 Jan; 99(1):159–67.

Publications Committee, Society for Maternal-Fetal Medicine, Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstet Gynecol. 2011 Sep; 205(3):191–8.

Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol. 2007 Jun; 196(6):514.e1–9.

Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks’ gestation: a randomized controlled trial. Obstet Gynecol.

Dec; 76(6):1070–5.

Magee LA, Yong PJ, Espinosa V, Côté AM, Chen I, von Dadelszen P. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens Pregnancy Off J Int Soc Study Hypertens Pregnancy. 2009;28(3):312–47.

Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks’ gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994

Sep; 171(3):818–22.

Churchill D, Duley L, Thornton JG, Jones L. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation. Cochrane Database Syst Rev. 2013; 7:CD003106.

Norwitz ER, Funai EF. Expectant management of severe preeclampsia remote from term: hope for the best, but expect the worst. Am J Obstet Gynecol. 2008 Sep; 199(3):209–12.

Astudillo R., Suy A., Alijotas-Reig J., Carreras E., Higueras T., Expectant management in pregnant women with early and severe preeclampsia and concomitant risk factors, Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health. 2013 Oct; 3(4): 235-241.

Cómo citar
(1)
Rendón, C. A.; Ortiz, R. A. Manejo Expectante En Preeclampsia Severa Lejos Del término. Revisión De La Literatura Y Protocolo De Manejo. Rev. Fac. Cienc. Salud Univ. Cauca 2013, 15, 32-35.
Publicado
2013-12-01
QR Code

Algunos artículos similares: